News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Eli Lilly just wrote a $2.8 billion check on a psychedelic nasal spray that won't have pivotal trial data until 2029, and the reasoning behind that bet reveals where Big Pharma thinks depression treatment is heading.
TowneBank currently trades at $36.11 per share and has shown little upside over the past six months, posting a middling return of 3%. The stock also fell short of the S&P 500’s 8.7% gain during that period.
The world’s energy economy is changing, for better or for worse. We are shifting away from fossil fuels and toward a model based on cleaner energy sources. While solar and wind power might get the headlines, nuclear energy almost certainly has a role in this changing energy scene.TipRanks Welcomes a New ETF – NYSE:RANK TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE. RANK tracks the perfo
Nokia is betting its Nvidia-powered AI-native network platform will fuel long-term growth, with Wall Street remaining broadly bullish.
IBM just posted the biggest single-day drop in its history after a weak earnings report. With volatility elevated, here's an options trade that pays you upfront to buy the stock at a discount.
Why is the Dow holding up while the Nasdaq sinks? Healthcare gains are offsetting the semiconductor carnage.
IDEX trades at $223.61 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 8.7%.
Raymond James said improving bookings and a recovering backlog have strengthened AeroVironment's growth outlook.
Novo Nordisk (NYSE:NVO) received European Commission marketing authorization for its oral Wegovy pill for weight management. The approval covers the European Union and represents the first GLP-1 receptor agonist in pill form cleared for this use in the region. This decision follows growing use of obesity therapies in the U.S. and other key markets. Novo Nordisk is already a major player in diabetes and obesity care, and the oral Wegovy pill gives the company another way to reach patients...
Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.
First Citizens BancShares currently trades at $2,070 per share and has shown little upside over the past six months, posting a small loss of 4.6%. The stock also fell short of the S&P 500’s 8.7% gain during that period.
Rocket Lab and Planet Labs have potential, but there is too much speculation in space stocks right now.
The stocks are at opposite ends of the valuation spectrum.
Vicor's AI-driven demand, rising backlog and stronger earnings support momentum, but premium valuation and execution risks leave modest upside.
Over the last six months, Alamo’s shares have sunk to $162.81, producing a disappointing 15.5% loss - a stark contrast to the S&P 500’s 8.7% gain. This might have investors contemplating their next move.
United Airlines' Q2 earnings beat estimates as strong yields and broad revenue gains offset soaring fuel costs and margin pressure.
J.B. Hunt's Q2 earnings beat estimates as intermodal growth, pricing and cost discipline lift revenues, operating income and margins.
Tower Semiconductor is making a bold $3 billion bet on Japan, expanding its manufacturing capacity and boosting investor confidence.
Gold miners just handed one of Wall Street's most punishing ETFs its best month in recent memory, and the reason has less to do with the metal itself than with a shift in the macro backdrop that caught a crowded trade completely off guard.
Advanced Micro Devices' market cap has more than doubled this year to around $840 billion.
Small-cap stocks are staging their most dominant run against the S&P 500 in over two decades, and three ETFs are competing for the best seat at the table. Which one actually comes out ahead may surprise you.
Abbott Laboratories (NYSE:ABT) shares rose nearly 11% on Thursday after the healthcare company reported second quarter 2026 results that topped Wall Street expectations and raised its full-year adjusted earnings guidance. The company posted adjusted diluted earnings per share of $1.31 for the...
UNH beats Q2 earnings estimates on lower medical costs and stronger Optum Insight, then raises its 2026 EPS and cash flow outlook.
ImmunityBio’s stock has surged 282.7% year to date, yet its overall valuation checks sit at a mixed 3 out of 6. This leaves investors weighing a powerful momentum story against signals that do not clearly flag the shares as cheap or expensive. The year to date gain of 282.7% suggests expectations around ImmunityBio have reset sharply higher. Fresh buyers are now paying a far richer price than they would have earlier in the year. Speculation around Anktiva’s potential role in bladder cancer...
Monolithic (MPWR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Microchip Tech (MCHP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Blackstone Inc. (BX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
General Motors (GM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.